journal article·2022-01-28Open access

The Evolution of Molecular Recognition: From Antibodies to Molecularly Imprinted Polymers (MIPs) as Artificial Counterpart

Ortensia Ilaria Parisi, Fabrizio Francomano, Marco Dattilo, Francesco Patitucci, Sabrina Prete, Fabio Amone, Francesco Puoci

Abstract

Molecular recognition is a useful property shared by various molecules, such as antibodies, aptamers and molecularly imprinted polymers (MIPs). It allows these molecules to be potentially involved in many applications including biological and pharmaceutical research, diagnostics, theranostics, therapy and drug delivery. Antibodies, naturally produced by plasma cells, have been exploited for this purpose, but they present noticeable drawbacks, above all production cost and time. Therefore, several research studies for similar applications have been carried out about MIPs and the main studies are reported in this review. MIPs, indeed, are more versatile and cost-effective than conventional antibodies, but the lack of toxicity studies and their scarce use for practical applications, make it that further investigations on this kind of molecules need to be conducted.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Analytical chemistry methods development · Mass Spectrometry Techniques and Applications · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy

Macrofarm s.r.l., c/o Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy

References (100+)

Show source-provided references
1. The many sides of Paul Ehrlich10.1038/ni.3601 ↗
2. Functions of antibodies10.1128/microbiolspec.AID-0019-2014 ↗
3. From B cell to plasma cell10.1385/IR:36:1:27 ↗
4. Disulfide bond structures of IgG molecules: Structural variations, chemical modifications and possible impacts to stability and biological function10.4161/mabs.4.1.18347 ↗
5. Structure and function of immunoglobulins10.1016/j.jaci.2009.09.046 ↗
6. Human antibody–Fc receptor interactions illuminated by crystal structures10.1038/nri1266 ↗
7. Goldberg’s theory of antigen-antibody reactions in vitro
8. The structural basis of antibody-antigen recognition
9. Membrane proteins with immunoglobulin-like domains—A master superfamily of interaction molecules10.1016/S1044-5323(03)00047-2 ↗
10. Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus10.1002/jmr.2352 ↗
11. A brief review of monoclonal antibody technology and its representative applications in immunoassays10.1080/15321819.2018.1515775 ↗
12. Khan, F.H. (2020). Antibodies and their applications. Animal Biotechnology, Elsevier.10.1016/B978-0-12-811710-1.00023-9 ↗
13. Prospective applications of single-domain antibodies in biomedicine10.1134/S0026893320030164 ↗
14. Radioimmunoassay: Review of basic principles10.1016/S0001-2998(75)80028-6 ↗
15. Chemiluminescent and bioluminescent techniques10.1093/clinchem/37.9.1472 ↗
16. A decade of development in immunoassay methodology10.1093/clinchem/36.8.1408 ↗
17. Lipid raft-associated protein sorting in exosomes10.1182/blood-2003-03-0871 ↗
18. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA)10.1373/clinchem.2005.051532 ↗
19. The history and future of the fluorescence activated cell sorter and flow cytometry: A view from Stanford10.1093/clinchem/48.10.1819 ↗
20. SERS-based immunoassay on 2D-arrays of Au@ Ag core–shell nanoparticles: Influence of the sizes of the SERS probe and sandwich immunocomplex on the sensitivity10.1039/C7RA00154A ↗
21. Sensitivity enhancement of forster resonance energy transfer immunoassays by multiple antibody conjugation on quantum dots10.1021/acs.bioconjchem.8b00296 ↗
22. Determining the architectures of macromolecular assemblies10.1038/nature06404 ↗
23. Lateral flow assays10.1042/EBC20150012 ↗
24. Antibody production and application for immunoassay development of environmental hormones: A review10.1186/s40538-018-0117-0 ↗
25. Solid-phase nuclear magnetic resonance immunoassay for the prostate-specific antigen by using protein-coated magnetic nanoparticles10.1007/s00604-019-3925-4 ↗
26. TaqStart Antibody: “hot start” PCR facilitated by a neutralizing monoclonal antibody directed against Taq DNA polymerase
27. Antibody-mediated catalysis: Induction and therapeutic relevance10.1016/j.autrev.2012.10.009 ↗
28. Antibody-guided nanomedicines as novel breakthrough therapeutic, diagnostic and theranostic tools10.1039/C9BM00931K ↗
29. Theranostic Applications of Antibody-Based Systems in Human Diseases10.1166/jbn.2018.2469 ↗
30. Pharmacokinetics of pegylated liposomal doxorubicin10.2165/00003088-200342050-00002 ↗
31. PEGylated gold nanoparticles conjugated to monoclonal F19 antibodies as targeted labeling agents for human pancreatic carcinoma tissue10.1021/nn800429d ↗
32. CD44v6 monoclonal antibody-conjugated gold nanostars for targeted photoacoustic imaging and plasmonic photothermal therapy of gastric cancer stem-like cells10.7150/thno.11632 ↗
33. Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer10.2147/IJN.S10881 ↗
34. Theranostic gold nanoantennas for simultaneous multiplexed Raman imaging of immunomarkers and photothermal therapy10.1021/acsomega.7b00527 ↗
35. Development of therapeutic antibodies for the treatment of diseases10.1186/s12929-019-0592-z ↗
36. Antibodies to watch in 201910.1080/19420862.2018.1556465 ↗
37. Rituximab in Hodgkin lymphoma: Is the target always a hit?10.1016/j.ctrv.2010.11.005 ↗
38. Hill, P., Cross, N.B., Barnett, A.N.R., Palmer, S.C., and Webster, A.C. (2017). Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Cochrane Database Syst. Rev., 1.10.1002/14651858.CD004759.pub2 ↗
39. The pharmacology and therapeutic applications of monoclonal antibodies10.1002/prp2.535 ↗
40. The increasingly human and profitable monoclonal antibody market10.1016/j.tibtech.2018.05.014 ↗
41. Next generation immune-checkpoints for cancer therapy10.21037/jtd.2018.02.79 ↗
42. Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease10.1136/annrheumdis-2011-201244 ↗
43. Safety and tolerability of adalimumab for the treatment of psoriasis: A review summarizing 15 years of real-life experience10.1177/2040622318772705 ↗
44. Treatment of Muckle-Wells syndrome: Analysis of two IL-1-blocking regimens
45. Updates in treatment of recurrent Clostridium difficile infection10.14740/jocmr3854 ↗
46. Raxibacumab: Potential role in the treatment of inhalational anthrax10.2147/IDR.S47305 ↗
47. Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sezary syndrome10.1517/14712590802528696 ↗
48. CGRP as the target of new migraine therapies—Successful translation from bench to clinic10.1038/s41582-018-0003-1 ↗
49. Monoclonal antibodies for treating osteoporosis10.1080/14712598.2018.1401607 ↗
50. Alving, C.R., Wassef, N.M., and Potter, M. (1996). Antibodies to cholesterol: Biological implications of antibodies to lipids. Immunol. Silicones, 181–186.10.1007/978-3-642-85226-8_18 ↗
51. Neidle, S. (2014). Antibody-Drug Conjugates Delivering DNA Cytotoxics. Cancer Drug Des. Discov, Elsevier. [2nd Ed.].
52. Yoo, J., Park, C., Yi, G., Lee, D., and Koo, H. (2019). Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers, 11.10.3390/cancers11050640 ↗
53. Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery10.1016/j.biomaterials.2006.09.047 ↗
54. Antibody-mediated drug delivery10.1016/j.ijpharm.2021.120268 ↗
55. Assessing the in vivo targeting efficiency of multifunctional nanoconstructs bearing antibody-derived ligands10.1021/nn4018922 ↗
56. The hybridoma revolution: An offshoot of basic research10.1002/(SICI)1521-1878(199911)21:11<966::AID-BIES9>3.0.CO;2-Z ↗
57. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains10.1073/pnas.81.21.6851 ↗
58. Replacing the complementarity-determining regions in a human antibody with those from a mouse10.1038/321522a0 ↗
59. Phage display derived monoclonal antibodies: From bench to bedside10.3389/fimmu.2020.01986 ↗
60. Monoclonal versus polyclonal antibodies: Distinguishing characteristics, applications, and information resources10.1093/ilar.46.3.258 ↗
61. Implementation of an antibody characterization procedure and application to the major ALS/FTD disease gene C9ORF7210.7554/eLife.48363 ↗
62. Bauer, M., Strom, M., Hammond, D.S., and Shigdar, S. (2019). Anything you can do, I can do better: Can Aptamers replace antibodies in clinical diagnostic applications?. Molecules, 24.10.3390/molecules24234377 ↗
63. Some ascites monoclonal antibody preparations contain contaminants that bind to selected Golgi zones or mast cells10.1177/42.2.7507139 ↗
64. Reproducibility: Standardize antibodies used in research10.1038/518027a ↗
65. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 210.1038/380548a0 ↗
66. Mallikaratchy, P. (2017). Evolution of complex target SELEX to identify aptamers against mammalian cell-surface antigens. Molecules, 22.10.3390/molecules22020215 ↗
67. Aptamers: An emerging class of molecules that rival antibodies in diagnostics10.1093/clinchem/45.9.1628 ↗
68. Wei, H., Li, B., Li, J., Wang, E., and Dong, S. (2007). Simple and sensitive aptamer-based colorimetric sensing of protein using unmodified gold nanoparticle probes. Chem. Commun., 3735–3737.10.1039/b707642h ↗
69. Functional nucleic acid probe for parallel monitoring K+ and protoporphyrin IX in living organisms10.1021/acs.analchem.5b04936 ↗
70. Current perspectives on aptamers as diagnostic tools and therapeutic agents10.3390/pharmaceutics12070646 ↗
71. Zhang, Y., Lai, B.S., and Juhas, M. (2019). Recent advances in aptamer discovery and applications. Molecules, 24.10.3390/molecules24050941 ↗
72. Affibody molecules as engineered protein drugs10.1038/emm.2017.35 ↗
73. Molecularly imprinted polymers: Antibody mimics for bioimaging and therapy10.1021/acs.chemrev.0c00428 ↗
74. Advantages of RGD peptides for directing cell association with biomaterials10.1016/j.biomaterials.2011.02.029 ↗
75. The functions and applications of RGD in tumor therapy and tissue engineering10.3390/ijms140713447 ↗
76. Advances in targeting the folate receptor in the treatment/imaging of cancers10.1039/C7SC04004K ↗
77. Parisi, O.I., and Puoci, F. (2015). Stimuli-responsive Molecularly Imprinted Polymers. Chemoresponsive Materials, Royal Society of Chemistry.10.1039/9781782622420-00364 ↗
78. Adsorption properties and structure of silica gel
79. The preparation of specific adsorbents10.1073/pnas.35.5.227 ↗
80. The use of polymers with enzyme-analogous structures for the resolution of racemates
81. Synthesis of substrate-selective polymers by host-guest polymerization10.1002/macp.1981.021820240 ↗
82. Characteristic and synthetic approach of molecularly imprinted polymer10.3390/i7050155 ↗
83. Enzyme-analogue built polymers and their use for the resolution of racemates10.1016/S0040-4039(01)87213-0 ↗
84. Enzyme-analogue built polymers, 4. On the synthesis of polymers containing chiral cavities and their use for the resolution of racemates10.1002/macp.1977.021781004 ↗
85. Recent advances in molecular imprinting technology: Current status, challenges and highlighted applications10.1039/c0cs00084a ↗
86. Drug assay using antibody mimics made by molecular imprinting10.1038/361645a0 ↗
87. Imprinting of amino acid derivatives in macroporous polymers10.1016/S0040-4039(01)81566-5 ↗
88. An acrylamide-based molecularly imprinted polymer for the efficient recognition of optical amino acid hydantoins10.1039/a902025j ↗
89. Cross-linked polyvinylpyrrolidones with increased affinity and specificity for methyl orange and its homologs10.1002/pol.1982.170200614 ↗
90. On the feasibility of using molecularly imprinted poly (Hema) as a sensor component10.1016/S0039-9140(96)02204-7 ↗
91. Molecular imprinting science and technology: A survey of the literature for the years up to and including 200310.1002/jmr.760 ↗
92. 1H nuclear magnetic resonance study of the molecular imprinting of (−)-nicotine: Template self-association, a molecular basis for cooperative ligand binding10.1016/j.chroma.2003.09.064 ↗
93. Molecular imprinting: A technique for producing specific separation materials10.1016/0167-7799(89)90006-1 ↗
94. A new method for the introduction of recognition site functionality into polymers prepared by molecular imprinting: Synthesis and characterization of polymeric receptors for cholesterol10.1021/ja00132a010 ↗
95. Molecularly imprinted polymers: A bridge to advanced drug delivery10.1016/j.addr.2005.07.010 ↗
96. Biomacromolecule template-based molecularly imprinted polymers with an emphasis on their synthesis strategies: A review10.1002/pat.3754 ↗
97. Integrating ionic liquids with molecular imprinting technology for biorecognition and biosensing: A review10.1016/j.bios.2019.111830 ↗
98. Molecularly imprinted polymer nanomaterials and nanocomposites by controlled/living radical polymerization10.1016/j.progpolymsci.2016.04.001 ↗
99. Molecularly imprinted polymer nanomaterials and nanocomposites: Atom-transfer radical polymerization with acidic monomers10.1002/ange.201412494 ↗
100. Preparation of molecularly imprinted polymer microspheres via reversible addition–fragmentation chain transfer precipitation polymerization10.1016/j.polymer.2009.04.053 ↗